Mr. Edward L. Erickson

• 
  press.abc-directory.com/press/3341 - [Cached Version]
  Published on: 7/22/2008    Last Visited: 9/29/2008  

  Y-Carbon, Inc. Announces the Appointment of Edward L. Erickson as CEO and Board MemberY-Carbon, Inc.
  ...
  Announces the Appointment of Edward L. Erickson as CEO and Board Member
  ...
  Y-Carbon, Inc., a nanotechnology startup developing an innovative method of making and tailoring novel, nanostructured carbon materials with applications in energy storage, medical products, life science research, filtration and purification systems, announced today that Edward L. Erickson has been appointed CEO and a Director.
  
  Mr. Erickson is a "serial entrepreneur" with extensive experience in start-up and early-stage companies, as well as large organizations, having served as president, CEO or director of a dozen such companies, four of which successfully completed IPOs during his tenure.He has raised more than $500M in equity and debt capital in both the private and public capital markets.Ed will serve Y-Carbon initially on a part-time basis pending completion of certain other entrepreneurial projects.
  
  During his 30 years of business and military experience, Ed has served in senior management positions as well as a consultant in the biotech, defense, energy and technology sectors.In addition to substantial operating and executive management background in biotechnology, Ed's experience includes consulting engagements in strategic and technology planning, system engineering and project management for clients that included major energy and natural resources-based corporations in the U.S. and Europe, the U.S. Department of Energy, the U.S. Department of Defense, and corporations controlled by European governments.He served as a military officer in the U.S. Navy's Nuclear Submarine Program aboard the U.S.S. Nautilus (SSN-571), the world's first nuclear submarine, during which time his responsibilities included supervision, operation and maintenance of the ship's electrical, nuclear, and steam plant systems.
  
  Ed holds a BS with distinction in Mathematics with a minor in Physics and an MS in Mathematics from the Illinois Institute of Technology.He received an MBA with high distinction from Harvard University where he was elected a Baker Scholar and was awarded the Loeb Rhodes Fellowship in Finance.Ed has received substantial recognition as a business leader, including being named the recipient of the 2004 Small Times Magazine "Best of Small Tech Business Leader" award in nanotechnology.
  ...
  Mr. Erickson said, "I am extraordinarily pleased to become a part of this exciting venture and I believe that the company's platform technology has the potential to make major contributions toward solving significant problems related to the global energy crisis and in other fields such as the practice of medicine."
  ...
  Y-carbon - Appointment - Edward L. Erickson - Ceo - Board Member

• 
  www.sec.gov/Archives/edgar/data/1228221/0001181431-08-0 - [Cached Version]
  Published on: 8/6/2008    Last Visited: 8/7/2008  

  0001228221 ERICKSON EDWARD L C/O BARRIER THERAPEUTICS, INC. 600 COLLEGE ROAD E, SUITE 3200 PRINCETON NJ 08540 1 0 0 0

• 
  phx.corporate-ir.net/phoenix.zhtml?c=142048&p=irol-news - [Cached Version]
  Published on: 1/3/2006    Last Visited: 9/14/2008  

  Barrier Therapeutics Appoints Edward L. Erickson to Its Board of Directors
  
  PRINCETON, NJ, Jan 03, 2006 (MARKET WIRE via COMTEX News Network) -- Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical company developing and commercializing products in the field of dermatology, today announced the appointment of Edward L. Erickson to its board of directors.Mr. Erickson has also been appointed as a member of the company's Governance and Nominating Committee.
  
  "We are very pleased to welcome Mr. Erickson to our Board of Directors," said Geert Cauwenbergh, Ph.D., Chairman and CEO of Barrier Therapeutics.
  ...
  Mr. Erickson is the Chairman of the Board of Directors of Immunicon Corporation (NASDAQ: IMMC), having served in this capacity since April 1998.From March 1999 through December 2005, he served as Immunicon's Chief Executive Officer (CEO) and from January 2000 until April 2005 as Immunicon's President.Mr. Erickson also currently serves as a director of Valeo Medical, Inc., a private biomedical products company.
  
  Prior to joining Immunicon, Mr. Erickson was the President and CEO and a director of DepoTech Corporation from 1993 to 1998.Mr. Erickson also served as the President and CEO and a director of Cholestech Corporation from 1991 to 1993.He served as a director of Tapestry Pharmaceuticals, Inc. from 2000 to 2005 and a director of Megabios Corporation from 1995 to 1998.
  
  From 1988 to 1991, Mr. Erickson was a senior executive in The Ares-Serono Group (now Serono, S.A.), where he held the position of President, Serono-Baker Diagnostics and Vice President, Financial Operations.Prior to that time, Mr. Erickson held senior management positions at Amersham International, plc.
  
  Mr. Erickson holds a B.S. with distinction in Mathematics with a minor in Physics and an M.S. in Mathematics from the Illinois Institute of Technology.He received an M.B.A. with high distinction from Harvard University where he was elected a Baker Scholar and received the Loeb Rhodes Fellowship in Finance.

• 
  www.bionanomatrix.com/our-team/board-of-directors - [Cached Version]
  Published on: 12/15/2008    Last Visited: 12/15/2008  

  Edward L. Erickson Consultant
  
  Edward Erickson is a well-known industry executive with extensive experience in the biotechnology industry. Currently a consultant to life science and venture capital firms, he serves on a number of private and public company boards. Previously, Mr. Erickson served as president, CEO and/or a director of over a dozen medical products firms, including Barrier Therapeutics, Cellatope Corporation, Cholestech, DepoTech, Immunicon and Megabios. Four of these firms successfully completed IPOs during his tenure. Earlier in his career he held senior management positions with Amersham International and Serono. Mr. Erickson earned B.S. and M.S. degrees from the Illinois Institute of Technology and an MBA from Harvard Business School.

• 
  pittsburgh.bizjournals.com/pittsburgh/stories/2007/10/1 - [Cached Version]
  Published on: 10/12/2007    Last Visited: 10/12/2007  

  Edward L. Erickson became the company's interim president and was named chairman, president and CEO earlier this year.The name change is still not official yet, Erickson said.

• 
  www.sec.gov/Archives/edgar/data/1173657/0001193125-08-0 - [Cached Version]
  Published on: 4/25/2008    Last Visited: 4/26/2008  

  Our Class I directors are Alfred Altomari, Charles F. Jacey, Jr., and Edward L. Erickson.
  ...
  Our Board has nominated Alfred Altomari, Charles F. Jacey, Jr., and Edward L. Erickson for election as the Class I directors.
  ...
  Charles F. Jacey, Jr. and Edward L. Erickson are existing directors, and Alfred Altomari was appointed by the Board on January 25, 2008.
  ...
  The persons named as proxy agents in the enclosed proxy card intend (unless instructed otherwise by a stockholder) to vote for the election of Alfred Altomari, Charles F. Jacey, Jr., and Edward L. Erickson as the Class I directors.
  ...
  Edward L. Erickson(2)(3)
  ...
  Edward L. Erickson has been our director since January 2006.Currently, Mr. Erickson is a consultant and advisor to life sciences-based companies and venture capital firms.He serves as the Chairman, and interim President and CEO of Cellatope Corporation, a private, development-stage company in the field of autoimmune disease diagnostics.He is a director of BioTrove, Inc., a private company that develops, manufactures and markets innovative instruments and consumables for genomic analysis, high-throughput screening and molecular diagnostics.Mr. Erickson also serves as a director of several other private medical products companies.From March 1999 to December 2005, Mr. Erickson served as the CEO of Immunicon Corporation, a NASDAQ-listed company focused on cell- and molecular-based human diagnostic and life science research products and analytical services to pharmaceutical and biotechnology companies, and from 1998 to 2007, served as Chairman of the Board of Immunicon.Previously, from 1993 to 1998, Mr. Erickson was the President and CEO of DepoTech Corporation, a biopharmaceutical company in the drug delivery field, and from 1991 to 1993, was the President and CEO of Cholestech Corporation, a diagnostics company in point-of-care cholesterol testing and screening.Earlier in his career he held senior management positions with Amersham International plc and The Ares-Serono Group.He has previously served as a director of other public and private medical products companies, including Tapestry Pharmaceuticals, Inc. (formerly NaPro Biopharmaceuticals, Inc.), a NASDAQ-listed pharmaceutical company, from 2000 to 2005.Mr. Erickson earned his B.S. and M.S. degrees from the Illinois Institute of Technology, and an MBA with high distinction from the Harvard Business School.
  ...
  03) Edward L. Erickson

• 
  www.biotrove.com/news_events/archived_press_peleases/20 - [Cached Version]
  Published on: 10/16/2006    Last Visited: 10/12/2008  

  BioTrove, Inc. Names Edward L. Erickson to Board of DirectorsBioTrove - News & Events - Archived Press Releases - Press Releases 2006
  ...
  Names Edward L. Erickson to Board of Directors
  
  —Sixth corporate director brings seasoned medical products industry perspective
  
  Woburn, MA, October 16, 2006 - BioTrove, Inc. today announced the appointment of Edward L. Erickson to its board of directors, reflecting BioTrove's increased emphasis on diagnostics and services.Mr. Erickson, current chairman of the board of Immunicon Corporation (NASDAQ: IMMC), expands the BioTrove board to six corporate directors.
  ...
  Mr. Erickson has served as president, CEO or a director for eight biomedical products companies, including Megabios Corporation, a gene therapy company (director, 1995-1998); DepoTech Corporation, a biopharmaceutical company in the drug delivery field (president and CEO, 1993-1998); Cholestech Corporation, a diagnostics company in point-of-care cholesterol testing and screening (president and CEO, 1991-1993); and most recently, Immunicon Corporation (NASDAQ-GM:IMMC), a company focused on cell- and molecular-based human diagnostic and life science research products and analytical services to pharmaceutical and biotechnology companies (CEO, 1999-2005), where he also served as chairman of the board since 1998.Earlier in his career he held senior management positions with Amersham International and Serono.
  
  Mr. Erickson earned BS and MS degrees from the Illinois Institute of Technology, and an MBA from the Harvard Business School.He did military service as an officer in the U.S. Navy, including duty aboard the U.S.S. Nautilus, the world's first nuclear submarine.
  
  "The perspective afforded by a career as accomplished and diverse as Ed's is an asset to BioTrove," said Albert A. Luderer, Ph.D., president and CEO, BioTrove.
  ...
  Mr. Erickson's fellow BioTrove board members include:

• 
  www.sec.gov/Archives/edgar/data/1228221/0001228221-07-0 - [Cached Version]
  Published on: 2/7/2007    Last Visited: 3/15/2007  

  0001228221 ERICKSON EDWARD L C/O IMMUNICON CORPORATION 3401 MASONS MILL RD, SUITE 800 HUNTINGDON VALLEY PA 19006 1 0 0 0

• 
  www.sec.gov/Archives/edgar/data/1173657/0001193125-07-1 - [Cached Version]
  Published on: 5/3/2007    Last Visited: 8/7/2008  

  Our Class I directors are Charles F. Jacey, Jr., Edward L. Erickson and Nicholas J. Simon III.
  ...
  Edward L. Erickson(2)(3)
  ...
  Edward L. Erickson has been our director since January 2006 and serves on our Governance and Nominating and Audit committees.Mr. Erickson is a consultant and advisor to life sciences companies and venture capital firms.He currently serves as the Chairman of the board of directors of Immunicon Corporation, a public medical products company, which position he has held since April 1998.Mr. Erickson served as Immunicon's Chief Executive Officer from March 1999 to December 31, 2005 and as its President from January 2000 to April 2005.From 1993 to 1998, Mr. Erickson served as President, Chief Executive Officer and as a director of DepoTech Corporation, at that time a publicly-traded pharmaceutical company in the drug delivery field.From 1991 to 1993, he served as President, Chief Executive Officer and as a director of Cholestech Corporation, a publicly-traded diagnostics company in the field of point-of-care testing and screening.Earlier in his career, Mr. Erickson held general and executive management positions with The Ares-Serono Group, then a publicly traded pharmaceutical company headquartered in Switzerland, and Amersham International plc, a British medical and life science research products company, now a unit of General Electric.Mr. Erickson holds a B.S. in Mathematics with a minor in Physics and an M.S. in Mathematics from the Illinois Institute of Technology, and an M.B.A. with high distinction from Harvard University.

• 
  www.sec.gov/Archives/edgar/data/891504/0001047469-04-01 - [Cached Version]
  Published on: 6/2/2004    Last Visited: 7/28/2004  

  Edward L. Erickson, 57, has served as a director since 2000.Since April 1998, he has served as Chairman of the Board of Immunicon Corporation, a publicly traded medical products company with technology for use in diagnostics, life science research, and therapeutic applications.He has also served as Chief Executive Officer of Immunicon since March 1999, its President since January 2000, and was its interim Chief Executive Officer from September 1998 to March 1999.Immunicon completed an initial public offering of common stock in April 2004.From 1993 to 1998, Mr. Erickson served as President, Chief Executive Officer and as a director of DepoTech Corporation, at that time a publicly traded pharmaceutical company in the drug delivery field.From 1991 to 1993, he served as President, Chief Executive Officer and as a director of Cholestech Corporation, a publicly traded diagnostics company in the field of point-of-care cholesterol testing and screening.Prior to his employment with Cholestech Corporation, Mr. Erickson held senior executive positions with The Ares-Serono Group, now Serono, and with Amersham International plc, now Amersham plc.From 1995 to 1998, Mr. Erickson served as a director of MegaBios Corporation, a gene therapy company.Mr. Erickson holds a B.S. in mathematics with a minor in Physics and an M.S. in mathematics from the Illinois Institute of Technology and an M.B.A. with high distinction from Harvard University, where he was elected a Baker Scholar and was awarded the Loeb Rhoades Fellowship in Finance.

Page:  1 2 3 4 5